Contatec提高了2026年的利润前景,指出尽管《医疗保健计划》费率有所变动,销售增长强劲,利润幅度增加。 Convatec raised 2026 profit outlook, citing strong sales growth and margin gains despite Medicare rate changes.

康瓦特集团有限公司重申其2025年全年预期,并预计2026年每股调整后的双位数收益增长,该公司在10月31日之前的有机收入增长率为6.3%,主要是新产品发布和运营改进. Convatec Group PLC reaffirmed its 2025 full-year guidance and projected double-digit adjusted earnings per share growth for 2026, citing strong organic revenue growth of 6.3% through October 31, driven by new product launches and operational improvements. 该公司预计2025年有机收入增长6.0%至6.5%,调整后的营业利润率为22.0%至22.5%,尽管有30个基点关税影响。 The company expects 6.0% to 6.5% organic revenue growth for 2025 and an adjusted operating profit margin of 22.0% to 22.5%, despite a 30 basis point tariff impact. 它预计2026年非创新马特里克斯销售的有机增长为5%至7%,并且继续扩大利润幅度,尽管由于2026年1月开始的新的医疗保健计划付款率,新马特里克斯面临着1%至2%的收入逆向。 It anticipates 5% to 7% organic growth in non-InnovaMatrix sales for 2026, with continued margin expansion, though InnovaMatrix faces a 1% to 2% revenue headwind due to a new Medicare payment rate starting January 2026. 在伦敦交易中,Contatec的股份上升了6%以上。 Convatec’s shares rose over 6% in London trading.